CClinicalTrials.gg
Active, not recruitingNCT05864300Updated Sep 4, 2026

Impact of Neurochecks on Sleep in Critically Ill Adults

An interventional study of Neurocheck frequency in Cerebral Aneurysm, sponsored by University of California, San Diego. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Background: Following acute brain injury (ABI), patients are monitored in the intensive care unit (ICU) where providers rely on frequent neurological examinations ("neurochecks") to assess for neurodeterioration. Serial neurochecks are part of guideline recommendations, but there is equipoise between hourly (Q1) and every-other-hour (Q2) evaluation. In the ICU, care-related awakenings occur frequently, but it is unclear if differential neurocheck frequencies result in differential sleep, providing the scientific premise for this proposal.

Population: Thirty patients (N=15 per group) who have undergone elective aneurysm coiling will be enrolled. On post-operative day (POD) 0, patients will be screened and approached for informed consent if they do not meet exclusion criteria, e.g., prior intracranial injury, sleep disorders, cognitive impairment, mechanical ventilation. Patients with elective aneurysm coiling are being chosen because they require ICU level of care following their intracranial procedure, but do not have structural brain injury or ongoing sedation needs that might impact sleep measurements.

Methods: Usual care: Patients are monitored every 15-30 minutes for up to 6 hours post-procedure, then Q1 or Q2 for up to 24 hours. If these patients remain stable, they are discharged home on post-operative day (POD) 1. Proposed Intervention: Enrolled patients will be randomized to Q1 or Q2 neurochecks following the institutionally required 6 hours of stable neurological and vascular checks. Once randomized, patients will undergo placement of electroencephalogram (EEG) with video, electrooculogram, and chin lead. The video EEG will be in place for at least 8 hours to include the overnight (10PM-6AM) time period. Following completion of the recording, the signals obtained will be reviewed by a blinded polysomnographic sleep technician for sleep characteristics including quantitative assessments of wakefulness, deep (N3) sleep, REM sleep, sleep efficiency, and sleep fragmentation and arousals. On POD1, patients and their nurse will fill out the Richards-Campbell Sleep Questionnaire to rate subjective sleep quality.

02

Conditions studied

  • Cerebral Aneurysm

Browse trials for

Keywords

  • neurocheck; sleep; neurological examination
03

In context

Intracranial Aneurysm

427 studies on the registry are indexed under Intracranial Aneurysm; 115 are open to participants now.

This study's planned enrollment of 30 is below the median of 110 across 207 interventional studies indexed under Intracranial Aneurysm.

Browse Intracranial Aneurysm studies →

Lead sponsor

University of California, San Diego is the lead sponsor of 958 studies on the registry; 191 are open to participants now.

Of its 110 completed or terminated interventional studies of FDA-regulated products, 70 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

a. Adult patients who are status post uncomplicated elective coiling of unruptured cerebral aneurysm.

Exclusion criteria

Exclusion Criteria:

  1. Patients with past or current intracranial injury or disease.
  2. Patients with known flow-limiting pathology of carotid arteries, vertebral arteries, or intracranial arteries.
  3. Incomplete resolution of aneurysm.
  4. Known sleep disorders (e.g., insomnia)
  5. Pregnancy.
  6. Incarceration.
  7. Inability to communicate in English
  8. Cognitive impairment or lack of decision-making capacity.
  9. Ongoing sedation.
  10. Mechanical ventilation
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Hourly Neurochecks

    Patients awakened for neurological exams every hour

    Behavioral: Neurocheck frequency

  • Active comparator
    Every-Other-Hour Neurochecks

    Patients awakened for neurological exams every-other-hour

    Behavioral: Neurocheck frequency

Interventions

  • BehavioralNeurocheck frequency

    Randomized to hourly or every-other-hour examinations

06

What researchers measure

Primary outcomes

  1. Sleep efficiency

    Ratio of total sleep time compared to time in bed, reported as a percentage

    Time frame: Within 24 hours of enrollment

Secondary outcomes

  1. Wakefulness

    Blinded quantitative assessment of time spent awake

    Time frame: Within 24 hour of enrollment

  2. REM Sleep

    Blinded quantitative assessment of time spent in REM sleep

    Time frame: Within 24 hour of enrollment

  3. Deep Sleep

    Blinded quantitative assessment of time spent in deep sleep

    Time frame: Within 24 hour of enrollment

  4. Arousals

    Blinded quantitative assessment of number of arousals (as defined by American Academy of Sleep Medicine)

    Time frame: Within 24 hour of enrollment

  5. Sleep quality (subjective)

    As measured by Richards Campbell Sleep Questionnaire

    Time frame: Within 24 hour of enrollment

07

Study locations

1 site
  • UC San Diego Health
    San Diego, California 92130, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864300
Lead sponsor
University of California, San Diego
Collaborators
National Institute on Aging (NIA)
Responsible party
Jamie Labuzetta (Clinical Professor of Neurosciences, University of California, San Diego) — Principal investigator
First posted
May 18, 2023
Start date
Aug 11, 2023
Primary completion
Jan 6, 2026
Completion
Oct 1, 2026 (estimated)
Last update
Sep 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion